Healthcare Services

Non-Proliferative Diabetic Retinopathy Market Size Forecast To Achieve $3.97 Billion By 2030 With 6.8% CAGR

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Non-Proliferative Diabetic Retinopathy Market By 2030 Based On Its 2026 Value?

The market size for non-proliferative diabetic retinopathy has demonstrated strong growth over recent years. It is anticipated to increase from $2.83 billion in 2025 to $3.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. Historically, this expansion has been driven by the high prevalence of diabetes, limited awareness concerning retinal complications, a continued reliance on conventional laser treatments, the low adoption rate of intravitreal injections, and an insufficient screening infrastructure.

The non-proliferative diabetic retinopathy market size is anticipated to undergo significant expansion in the coming years. It is projected to climb to $3.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. The expansion during this forecast period stems from the increasing incidence of diabetic retinopathy, the growing uptake of anti-VEGF and steroid therapies, the proliferation of ophthalmology clinics and specialized centers, advancements in retinal imaging technologies, and improved patient awareness and early diagnosis efforts. Prominent trends for the forecast period include the rising adoption of anti-VEGF therapy in NPDR, increased application of intraocular steroid injections, expanding implementation of sophisticated laser surgery techniques, broader deployment of vitrectomy procedures, and the advancing integration of AI-powered retinal imaging and diagnosis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp

Which Drivers Are Advancing The Non-Proliferative Diabetic Retinopathy Market Growth?

The increasing prevalence of diabetes is anticipated to drive the expansion of the non-proliferative diabetic retinopathy market moving forward. Diabetes is defined as a chronic metabolic disorder characterized by elevated blood glucose, resulting from either insufficient insulin production by the pancreas or the body’s cells becoming resistant to insulin’s effects. This condition is primarily attributed to sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes leads to non-proliferative diabetic retinopathy by causing damage to the blood vessels in the retina, largely due to prolonged exposure to high glucose levels in the bloodstream, which can result in vision impairment and potential blindness. For instance, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, an additional 549,000 individuals in England were identified at risk of developing type 2 diabetes. This increased the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This figure marks a notable rise compared to 3,065,825 in 2022, representing an increase of nearly 20%. Therefore, the growing occurrence of diabetes is a significant factor fueling the growth of the non-proliferative diabetic retinopathy market.

Which Segment-Based Categories Are Covered In The Non-Proliferative Diabetic Retinopathy Market?

The non-proliferative diabetic retinopathy market covered in this report is segmented –

1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy

2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)

2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)

3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation

4) By Vitrectomy: Pars Plana Vitrectomy (PPV), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)

What Trends Are Shaping The Non-Proliferative Diabetic Retinopathy Market Structure?

Leading companies in the non-muscle invasive bladder cancer market are prioritizing the development of innovative products, such as immunotherapy, to enhance treatment possibilities and outcomes for patients. Immunotherapy operates by leveraging the body’s immune system to identify and attack cancer cells through boosting or activating immune responses. For instance, in March 2024, ImmunityBio Inc., a US-based biotechnology company, obtained approval from the Food and Drug Administration (FDA) for ANKTIVA (N-803) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) exhibiting carcinoma in situ (CIS), with or without papillary tumors. This approval stems from encouraging clinical trial results, which indicated that ANKTIVA, when used in conjunction with Bacillus Calmette-Guérin (BCG), presents a viable treatment pathway for patients who had not responded to standard BCG therapy. ANKTIVA is a pioneering IL-15 agonist immunotherapy that functions by strengthening the immune system, specifically stimulating natural killer (NK) cells and CD8+ killer T cells to target and eradicate cancer cells.

Which Key Players Are Active In The Non-Proliferative Diabetic Retinopathy Market?

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Kowa Company Ltd.

Access The Complete Non-Proliferative Diabetic Retinopathy Market Report:

https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

Which Region Holds The Largest Share In The Non-Proliferative Diabetic Retinopathy Market?

North America was the largest region in the non-proliferative diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Non-Proliferative Diabetic Retinopathy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=15620&type=smp

Browse Through More Reports Similar to the Global Non-Proliferative Diabetic Retinopathy Market 2026, By The Business Research Company

Bladder Cancer Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Adrenocortical Carcinoma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/adrenocortical-carcinoma-global-market-report

Urothelial Carcinoma Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795